JAK1
-
药时代BD项目 | 每日一次口服JAK1/TYK2双靶点透脑小分子抑制剂
TYK2/JAK1双重抑制剂 首次从自免杀入神经系统疾病 越来越多的研究表明，炎症反应在阿尔茨海默病（AD）和帕金森病（PD）等神经退行性疾病的发病机制中扮演着关键角…
-
【IND enabling】Once daily oral brain-penetrant dual JAK1/TYK2 inhibitor with better efficacy and safety【Product for Licensing】
Project ID：DT-202500428-041 Product Brief Summary More highlights Contact us: For any ques…
-
Morphic’s stock prices soar by 75%! Eli Lilly invests an additional $3.2 billion in the autoimmune field
DrugTimes will present more reports timely. Please stay tuned
